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Melanoma metastasis is a devastating outcome
lacking an effective preventative therapeutic. We
provide pharmacologic, molecular, and genetic evi-
dence establishing the liver-X nuclear hormone re-
ceptor (LXR) as a therapeutic target in melanoma.
Oral administration of multiple LXR agonists sup-
pressed melanoma invasion, angiogenesis, tumor
progression, and metastasis. Molecular and genetic
experiments revealed these effects to be mediated
by LXRb, which elicits these outcomes through
transcriptional induction of tumoral and stromal
apolipoprotein-E (ApoE). LXRb agonism robustly
suppressed tumor growth and metastasis across a
diverse mutational spectrum of melanoma lines.
LXRb targeting significantly prolonged animal
survival, suppressed the progression of estab-
lished metastases, and inhibited brain metastatic
colonization. Importantly, LXRb activation displayed
melanoma-suppressive cooperativity with the
frontline regimens dacarbazine, B-Raf inhibition,
and the anti-CTLA-4 antibody and robustly in-
hibited melanomas that had acquired resistance
to B-Raf inhibition or dacarbazine. We present a
promising therapeutic approach that uniquely acts
by transcriptionally activating a metastasis suppres-
sor gene.INTRODUCTION
Metastasis, the dissemination of cancer cells from a primary
tumor to distal organs, accounts for the majority of deaths
incurred by solid tumors (Gupta and Massague´, 2006; Hanahan
and Weinberg, 2011; Talmadge and Fidler, 2010). The molecu-
lar and cell-biological complexity of metastatic progression,
as well as its devastating toll on society, have triggered exten-
sive investigations, leading to the identification of many coding
and noncoding genes as regulators of the metastatic process986 Cell 156, 986–1001, February 27, 2014 ª2014 Elsevier Inc.(Kang et al., 2003; Minn et al., 2005; Ma et al., 2007; Tavazoie
et al., 2008; Png et al., 2012; Pencheva et al., 2012). In the
past three decades, interdisciplinary preclinical and clinical
efforts aimed at reducing metastatic relapse have lowered
mortality rates and extended survival times for a number of
cancer types. This is especially the case for hormonally driven
malignancies, such as breast and prostate cancers, for
which nuclear hormone receptor targeting of the estrogen or
androgen receptors has proved to be an effective therapeutic
approach (Deblois and Gigue`re, 2013; Tran et al., 2009; Scher
et al., 2012).
Although nuclear hormone receptors have emerged as key
therapeutic targets in breast and prostate malignancies, whose
initiation and progression are intricately linked to the estrogen
and testosterone sex hormones, the clinical potential of nuclear
hormone receptor targeting in other solid cancers originating
from nonreproductive tissues is unexplored. Melanoma, the
most aggressive type of skin cancer with steeply increasing
incidence, incurs 48,000 deaths annually worldwide (Lucas
et al., 2006). Presently, there are no effective therapies for the
prevention of melanoma metastasis, with interferon-alpha, the
only Food and Drug Administration (FDA)-approved melanoma
adjuvant therapy, conferring a meager 5-year overall survival
benefit of 1%–3% (Garbe et al., 2011). The poor clinical prog-
nosis and the lack of curative therapies for patients with
advanced melanoma necessitate the development and imple-
mentation of novel approaches that prevent metastatic relapse
of this cancer.
We herein demonstrate that targeting of a specific nuclear hor-
mone receptor exhibits broad-spectrum efficacy in suppressing
melanoma progression. We identify the nuclear hormone recep-
tor LXRb as themajor LXR isoform expressed bymelanoma cells
and show that pharmacologic modulation of LXRb strongly
inhibits melanoma progression phenotypes of cell invasion,
endothelial recruitment, tumor progression, andmetastatic colo-
nization. LXRb activation suppresses melanoma progression
through the transcriptional induction of cancer-derived and
stromal ApoE—a potent metastasis suppressor in melanoma
(Pencheva et al., 2012). Our findings from multiple mutationally
diverse preclinical models of melanoma progression motivate
the clinical testing of LXRb targeting for the treatment of
metastatic melanoma.
(legend on next page)
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RESULTS
Identification of LXRb Signaling as a Therapeutic Target
in Melanoma
We had previously identified ApoE as a robust suppressor of
melanoma metastasis (Pencheva et al., 2012). We hypothesized
that the transcriptional induction of ApoE might suppress mela-
noma progression. The impact of such ApoE activation might be
heightened if an ApoE trans-activator would be expressed
across melanoma and in normal tissues. Previously, analysis of
nuclear hormone receptor expression in the NCI60 cell line
collection had revealed several receptors to exhibit stable
expression in melanoma (Holbeck et al., 2010). Notably, of these
nuclear receptors, the liver-X receptors (LXRs) had been previ-
ously found to enhance transcription of ApoE and other targets
in adipocytes and macrophages (Laffitte et al., 2001), whereas
pharmacologic activation of retinoid X receptors (RXRs) had
been shown to drive the expression of ApoE as well (Mak
et al., 2002). We further confirmed the expression of LXRs and
RXRs in melanoma and detected expression of LXRb and
RXRb in seven independently established primary melanoma
lines obtained from multiple melanoma patients (Figure 1A).
Given the ubiquitous basal expression of LXRb andRXRb in mel-
anoma, the recently uncovered metastasis-suppressive role of
ApoE (Pencheva et al., 2012), and the availability of pharmaco-
logic agents to therapeutically activate LXRs and RXRs, we
investigated whether activation of LXRs or RXRs might inhibit
melanoma progression phenotypes. We first examined whether
pharmacologic agonism of LXRs or RXRs in melanoma cells
affects in vitro cell growth. Treatment of melanoma cells with
two structurally distinct LXR agonists, GW3965 or T0901317,
or the RXR agonist bexarotene did not affect cell proliferation
or viability rates (Figures S1A–S1F available online). We next
assessed the effects of LXR or RXR activation on cell invasion
and endothelial recruitment—phenotypes displayed by meta-
static melanoma and metastatic breast cancer populations
(Pencheva et al., 2012; Png et al., 2012). Treatment of the muta-
tionally diverseMeWo, HT-144, and SK-Mel-2 humanmelanoma
lines as well as the SK-Mel-334.2 primary human melanoma line
with LXR agonists consistently suppressed melanoma invasion
through matrigel (Figures 1B–1E) and endothelial recruitment
by melanoma cells in trans-well assays (Figures 1F–1J). In com-
parison, treatment with the RXR agonist bexarotene suppressed
invasion in only half of the melanoma lines tested and did not
significantly affect endothelial recruitment (Figures 1B–1J), sug-
gesting that RXR activation might modulate an effector that
antagonizes the effects of ApoE on these phenotypes. GivenFigure 1. LXRb Activation Suppresses Melanoma Progression Phenot
(A) Heatmap of mRNA expression levels of LXR and RXR isoforms in primary m
(MSKCC).
(B–E) Matrigel invasion by 1 3 105 MeWo (B), 5 3 104 HT-144 (C), 5 3 104 SK-M
GW3965, T0901317, or bexarotene at 1 mM for 72 hr. nR 4.
(F–I) 53 104 MeWo (F), HT-144 (G), SK-Mel-2 (H), and SK-Mel-334.2 (I) melanoma
were tested for their ability to recruit 1 3 105 endothelial cells in trans-well assay
(J) Representative thresholded images of endothelial cells recruited by melanom
(K–N) 13 105 MeWo and HT-144 melanoma cells expressing a control short hairp
invasion (K and L) and endothelial recruitment (M and N) assays following treatm
All data are represented as mean ± SEM. Scale bars, 50 mm. *p < 0.05, **p < 0.0
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requirement for LXR signaling in mediating the suppressive
effects of LXR agonists by depleting each LXR isoform in mela-
noma cells. Knockdown of melanoma cell LXRb, but not LXRa,
abrogated the ability of GW3965 and T0901317 to suppress
invasion and endothelial recruitment (Figures 1K–1N and S1G–
S1J), revealing melanoma cell LXRb to be the effector of LXR
agonists in suppressing these phenotypes. Importantly, LXRb
was the predominant LXR isoform expressed by melanoma cells
(Figure 1A, p < 0.0001) and was also ubiquitously expressed
across primary and metastatic human melanoma clinical sam-
ples (Figures S1K and S1L).
Therapeutic Delivery of LXR Agonists Suppresses
Melanoma Tumor Growth
We next investigated the therapeutic impact of LXR agonists
on melanoma. Orally administering low doses (20 mg/kg) of
GW3965 or T0901317 to immunocompetentmice bearing estab-
lished subcutaneous B16F10 mouse melanoma tumors sup-
pressed tumor growth by 67% and 61%, respectively (Figures
2A and 2B), whereas administering a higher LXR agonist dose
(100 mg/kg) reduced tumor growth by 80% (Figure 2A). For all
subsequent studies, we utilized GW3965, given its lower EC50
for LXRb (Collins et al., 2002). Oral administration of GW3965
also robustly suppressed tumor growth by the MeWo (70% inhi-
bition) and SK-Mel-2 (49% inhibition) human melanoma cell
lines, as well as the SK-Mel-334.2 primary human melanoma
line (73% inhibition) (Figures 2C–2E and S2A). Encouraged by
the robust tumor-suppressive impact of LXR agonists on estab-
lished small tumors (5–10 mm3) (Figures 2A–2E), we next found
that LXR activation therapy also inhibited the growth of large
(150 mm3) tumors by 50% (Figure 2F). Remarkably, GW3965
therapy elicited partial tumor regression and stabilization of
tumor growth by the B-Raf wild-type MeWo line beyond
100 days (Figure 2G). Importantly, all members of this entire
GW-treated cohort remained alive beyond 120 days (Figure 2H).
Administering GW3965 after tumor establishment also pro-
longed overall survival times in an immunocompetent model
and a primary human graft model (Figures S2B and S2C). Taken
together, these findings are consistent with broad-spectrum
efficacy of LXR activation therapy across melanotic and amela-
notic melanoma tumors of diverse mutational subtypes: B-Raf
and N-Ras wild-type (Figures 2A–2C), B-Rafmutant (Figure 2D),
and N-Ras mutant (Figure 2E).
GW3965 administration substantially reduced the number as
well as the size of endothelial vessels present in tumors (Figures
2I–2K and S2D–S2F). This was accompanied by a modestypes
elanoma lines from patients at the Memorial Sloan Kettering Cancer Center
el-2 (D), and 5 3 104 SK-Mel-334.2 (E) melanoma cells treated with DMSO,
cells, treated with DMSO, GW3965, T0901317, or bexarotene at 1 mM for 72 hr,
s. nR 4.
a cells.
in RNA (shRNA) or shRNAs targeting LXRa or LXRbwere subjected to matrigel
ent with DMSO, GW3965, or T0901317 at 1 mM for 72 hr. nR 4.
1, ***p < 0.001, ****p < 0.0001. See also Figure S1.
Figure 2. Therapeutic LXR Activation Inhibits Melanoma Tumor Growth
(A and B) Tumor growth by 5 3 104 B16F10 cells subcutaneously injected into C57BL/6 mice. Following tumor growth to 5–10 mm3 in volume, mice were fed
a control chow or a chow supplemented with GW3965 (20 mg/kg or 100 mg/kg) (A) or T0901317 (20 mg/kg) (B). Representative tumor images correspond to
day 12. nR 8.
(C–E) Tumor growth by 13 106 MeWo (C), 7.53 105 SK-Mel-334.2 (D), and 23 106 SK-Mel-2 (E) human melanoma cells in immunocompromised mice that were
fed a control diet or a GW3965 diet. nR 8 (C and D); n = 5 (E).
(F) Following B16F10 tumor growth to 150 mm3, mice were administered a control diet or a GW3965 diet (100 mg/kg). nR 6.
(G) Mice bearing MeWo tumor burden from (C) were monitored for the long-term progression of their GW3965-treated tumors. nR 8.
(H) Survival of mice from (C) bearing MeWo melanoma burden in response to a control diet or a GW3965 diet (100 mg/kg) treatment. nR 4.
(I–K) Number (I) and size (J) of CD31-positive endothelial vessels and endothelial cell density (K) in MeWo tumors following treatment with a control diet or a
GW3965 diet for 35 days. n = 5.
(L) Ki-67-positive cells detected in MeWo tumors in response to GW3965 treatment. n = 5.
All data are represented as mean ± SEM. Scale bars, 5 mm (A–D), 10 mm (K), 80 mm (L). See also Figure S2.decrease (23%) in the number of actively proliferating tumor cells
in vivo (Figure 2L) without a change in the number of apoptotic
cells (Figure S2G). These results suggest that, in addition to
reducing invasion, LXR activation suppresses melanoma tumor
growth primarily through inhibiting tumor angiogenesis with a
resulting reduction in in vivo tumor cell proliferation.LXR Agonism Suppresses Melanoma Metastasis to the
Lung and Brain
The strong suppressive effects of LXR agonists on melanoma
tumor growth motivated us to examine whether LXR activation
could also suppress metastatic colonization by melanoma cells.
Remarkably, mice that were orally administered GW3965 orCell 156, 986–1001, February 27, 2014 ª2014 Elsevier Inc. 989
Figure 3. LXR Agonism Suppresses Melanoma Metastasis
(A and B) Bioluminescence imaging of lung colonization by 43 104MeWo cells intravenously injected into NODSCIDmice that were fed a control chow or a chow
containing GW3965 or T0901317 at 20 mg/kg starting 10 days prior to cell injection. nR 5.
(C and D) Lung metastasis following intravenous injection of 2.53 105 HT-144 (C) and 43 104 SK-Mel-334.2 (D) melanoma cells into mice assigned to a control
diet or a GW3965 diet (20 mg/kg) 10 days prior to injection. nR 5.
(E and F) Brain and systemic photon flux following intracardiac injection of 13 105MeWo brain-metastatic melanoma cells into athymic nudemice that were fed a
control diet or a GW3965 diet (100 mg/kg) starting immediately postinjection. nR 6.
(G and H) Lung colonization by orthotopically disseminatedMeWo cells in NODSCIDmice that were administered a control diet or a GW3965 diet (100mg/kg) for
1 month following the excision of size-matched subcutaneous MeWo tumors. Representative vimentin-stained lungs are shown on the right. nR 7.
(legend continued on next page)
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T0901317 exhibited 31- and 23-fold less lungmetastatic burden,
respectively, from humanMeWo cells (Figures 3A and 3B). Treat-
ment also suppressedmetastatic colonization by the HT-144 line
(Figure 3C) as well as the SK-Mel-334.2 primary human line (Fig-
ure 3D). Additionally, oral administration of GW3965, a lipophilic
molecule, inhibited both brain metastatic colonization and
systemic metastasis following intracardiac injection of brain-
metastatic melanoma cells derived from the MeWo parental
line (Figures 3E and 3F). These results reveal robust metastasis
suppression by LXR activation therapy across multiple mela-
noma lines and in multiple distal organ metastatic sites.
We next tested the effects of LXR agonism on orthotopic
metastasis (Figure 3G). Oral administration of GW3965 posttu-
mor resection inhibited lung colonization by disseminated mela-
noma cells by 17-fold (Figure 3H). Remarkably, initiating therapy
after incipient metastases had progressed by 8-fold from the
baseline at seeding also dramatically suppressed (28-fold)
metastatic colonization (Figure 3I) and reduced the number of
macroscopic nodules observed (Figure 3J). Finally, treatment
in this preclinical ‘‘adjuvant’’ paradigm significantly prolonged
survival times following metastatic dissemination (Figure 3K).
LXRb Activation Suppresses Melanoma Phenotypes by
Transcriptionally Inducing Melanoma Cell ApoE
Expression
The inhibitory effects of LXR agonists on cell-extrinsic endothe-
lial recruitment by melanoma cells are consistent with the action
of a secreted molecule. Transcriptomic profiling revealed 41
secreted factors to be significantly upregulated in human
MeWo melanoma cells in response to GW3965 treatment (Table
S1). Interestingly, we identified ApoE, a previously validated
transcriptional target of LXRs in macrophages and adipocytes
(Laffitte et al., 2001), as the top upregulated secreted factor.
Quantitative real-time PCR (qRT-PCR) validation confirmed the
robust LXR-dependent upregulation of ApoE transcript expres-
sion in multiple melanoma lines (Figures S3A–S3C).
In light of the previously reported metastasis-suppressive
function of ApoE in melanoma (Pencheva et al., 2012), we inves-
tigated whether LXRb activation suppressesmelanoma progres-
sion through transcriptional induction of ApoE. Indeed, GW3965
and T0901317 enhanced the activity of an ApoE promoter/LXR
enhancer element reporter (Laffitte et al., 2001) in melanoma
cells (Figure 4A), whereas chromatin immunoprecipitation
(ChIP) confirmed endogenous LXRb binding of the ApoE multi-
enhancer element (Figure 4B). Importantly, LXR activation raised
both intracellular (Figures 4C–4E) and secreted ApoE protein
levels (Figures 4F, 4I, S3D). Notably, antibody-mediated neutral-
ization of ApoE completely prevented the LXRb agonist-medi-
ated suppression of cell invasion and endothelial recruitment
(Figures 4G, 4H, 4J, 4K, S3E, and S3F), revealing the effects of
LXR agonism to be mediated by extracellular ApoE. Additionally,(I) Lung colonization by 43 104 intravenously injected MeWo cells. Following inci
diet (100 mg/kg). n = 6.
(J) Macroscopic metastatic nodules in H&E-stained lungs extracted at day 77 fro
(K) Overall survival following intravenous injection of 43 104 MeWo cells. Mice w
injection. nR 5.
All data are represented as mean ± SEM.ApoE knockdown also blocked the GW3965-mediated suppres-
sion of these phenotypes (Figures S3G and S3H). In agreement
with this, melanoma cell depletion of LXRb, but not LXRa,
abrogated the ability of GW3965 and T0901317 to upregulate
ApoE transcript and protein expression (Figures 4L, 4M, and
S3I–S3K). Collectively, these findings indicate that pharmaco-
logic activation of LXRb suppresses melanoma invasion and
endothelial recruitment by transcriptionally activating melanoma
cell ApoE expression.
Engagement ofMelanoma-Derived and StromalApoE by
LXRb Activation Therapy
The LXRb-induced suppression of keymelanomaphenotypes by
extracellular ApoE in vitro suggests that the suppressive effects
of LXR agonists in vivo might be further augmented by the acti-
vation of LXRs in peripheral tissues, which could serve as addi-
tional sources of extracellular ApoE. We found that treatment of
mice with either GW3965 or T0901317 significantly elevated
ApoE expression in melanoma tumors, metastases (Figures
S4A–S4E), systemic adipose, lung, and brain tissues of mice
(Figures 5A and 5B), and in circulating white blood cells (Fig-
ure 5C). These results indicate that LXR activation therapy
induces ApoE expression in melanoma tumors and in various
tissues and organs.
We next investigated the tissue compartments that GW3965
acts on to mediate its tumor-suppressive effects. Interestingly,
GW3965 fully inhibited the growth of primary tumors formed by
LXRb-depleted cells (Figures 5D and S4F–S4H), implicating a
role for melanoma-extrinsic (stromal) LXR activation in tumor
suppression by GW3965. Genetic inactivation of stromal LXRb,
but not LXRa, rendered GW3965 completely ineffective (Figures
5D, S4M, and S4N). These findings reveal melanoma-extrinsic/
stromal LXRb to be the primary molecular target and effector
of GW3965 inmediating long-termmelanoma tumor growth sup-
pression. To test whether melanoma cell LXRb activation con-
tributes to the initial phase of tumor initiation and formation, we
pretreated melanoma cells with GW3965, allowing us to isolate
melanoma-intrinsic from stromal effects of the LXR agonist treat-
ment. Interestingly, whereas GW3965 pretreatment modestly
suppressed primary tumor formation and metastatic tumor initi-
ation in melanoma cells expressing LXRb, the drug failed to
inhibit these phenotypes in melanoma cells depleted of LXRb
(Figures S4I–S4L), consistent with melanoma cell LXRb partly
mediating the suppressive effects of GW3965 on the early stage
of tumor formation.
We next examined whether ApoE is the downstream effector
of in vivo melanoma suppression by LXR agonists. Stromal
ApoE was found to be required for GW3965-induced tumor
growth suppression as melanoma tumors implanted into
ApoE-null mice exhibited no growth reduction in response to
GW3965 administration (Figure 5E). Accordingly, melanomapient metastases formation, mice were assigned to a control diet or a GW3965
m mice shown in (I). nR 4.
ere assigned to a control diet or a GW3965 diet (20 mg/kg) 10 days prior to cell
Cell 156, 986–1001, February 27, 2014 ª2014 Elsevier Inc. 991
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cell depletion of ApoE had no effect on GW3965-induced tumor
growth suppression (Figures 5E and S4F–S4H). These findings
reveal that the tumor suppressive effects of GW3965 are primar-
ily mediated through extracellular ApoE derived from various
peripheral stromal tissues and supplied to the tumor via the
circulation and/or ApoE production by local stromal cells in the
microenvironment. Consistent with this, GW3965 treatment
significantly upregulated ApoE expression in macrophages
(158%), leukocytes (103%), and endothelial cells (20%)within tu-
mors (Figures 5F–5I).
Interestingly, metastasis suppression by GW3965 was entirely
occluded only in the setting of combined melanoma cell
depletion and genetic inactivation of ApoE (Figure 5J). We
thus conclude that the effects of LXRb on primary tumor
growth are elicited primarily through stromal ApoE activation,
whereas its effects on metastasis are mediated through ApoE
transcriptional induction in both the tumoral and stromal
compartments.
Consistent with a role for ApoE in human melanoma progres-
sion, we found that patients whose melanomas had metasta-
sized exhibited roughly 3-fold lower ApoE expression in their
primary tumors relative to patients whose melanomas had not
metastasized (Figure 5K). Remarkably, ApoE expression levels
robustly stratified patients at high risk from those at low risk for
metastatic relapse (Figure 5L) and predicted overall patient’s
survival (Figure 5M). Consistent with this, distal melanoma
metastases displayed significantly lower ApoE levels relative to
primary lesions in two independent TMA melanoma progression
sets (Figure S5A; Pencheva et al., 2012).
LXRb Activation Inhibits Melanoma Progression in a
Genetically Driven Mouse Model
Todeterminewhether LXRbactivation could suppressmelanoma
progression in a genetic model, we induced melanomas in Tyr::
CreER; B-RafV600E/+; Ptenlox/+ and Tyr::CreER; B-RafV600E/+;
Ptenlox/lox mice (Dankort et al., 2009) by intraperitoneal adminis-
tration of 4-hydroxytamoxifen (4-HT).Notably, oral administration
of GW3965 following melanoma initiation attenuated tumor pro-
gression and significantly extended the overall survival times of
both Pten heterozygous and Pten-null Tyr::CreER; B-RafV600E/+Figure 4. LXRb Activation Transcriptionally Enhances ApoE Expressio
(A) Luciferase activity driven off an ApoE promoter construct fused toME.1 orME.
or T0901317 at 1 mM for 24 hr. nR 4.
(B) ChIP of genomic ME.2 DNA in MeWo cells using an endogenous LXRb antib
ME.2 region containing the LXR binding element (LXRE-pos). Data are express
(LXRE-neg). nR 3.
(C–E) ApoE protein levels in MeWo (C), HT-144 (D), and SK-Mel-334.2 (E) cells trea
normalized to tubulin. nR 3.
(F) Extracellular ApoE levels quantified by ELISA in conditioned media from MeW
(G and H) Matrigel invasion and endothelial recruitment by MeWo cells, treated
neutralization antibody (1D7) or IgG added at 40 mg/ml. nR 6.
(I) Extracellular ApoE levels in conditioned media from SK-Mel-334.2 primary hu
(J and K) 53 104 SK-Mel-334.2 cells, pretreated with DMSO or GW3965 at 1 mM f
(K) assays in the presence of 1D7 or IgG antibodies. nR 7.
(L) Luciferase-based activity of an ApoE promoter +ME.1/ME.2 construct transfe
LXRb in response to DMSO or GW3965 (1 mM) treatment for 24 hr. nR 3.
(M) Extracellular ApoE protein levels in MeWo cells transduced with a control shR
(1 mM) for 72 hr. nR 3.
All data are represented as mean ± SEM. Scale bars, 50 mm. See also Table S1mice (Figures 6A, 6B, S6A, and S6B). Moreover, LXR agonist
treatment significantly reduced thenumber of lymphaticmetasta-
ses (Figure 6C).
Additionally, GW3965 therapy robustly inhibited tumor growth
and lung metastasis by CDKN2A/; B-RafV600E/+; Pten/ pri-
mary mouse melanoma cells injected into syngeneic immuno-
competent mice and extended the overall survival of mice
bearing B-RafV600E/+; Pten/; CDKN2A/ melanoma burden
(Figures 6D–6F). Collectively, these findings indicate that LXRb
activation reduces primary tumor progression, orthotopic and
experimental metastasis, andmortality rates in genetically driven
melanoma models.
LXRb Activation Suppresses Melanomas Resistant to
Dacarbazine and Vemurafenib
In order to test the effect of LXRb-activation therapy on popula-
tions that have acquired resistance to approved melanoma ther-
apies, we in vitro derived a B16F10 clone that showed a 7-fold
increase in survival when cultured in high-dose dacarbazine
(DTIC) (Figure S6C) and displayed in vivo resistance relative to
its parental line (Figures 6G and 6H). Of note, GW3965 adminis-
tration robustly suppressed tumor growth by this DTIC-resistant
subline by more than 70% (Figures 6H and 6I). Remarkably, oral
delivery of GW3965 also strongly inhibited (70%) the growth of
an independent in vivo selected DTIC-resistant MeWo subline
(Figures 6J–6L).
GW3965 treatment also suppressed the growth of two previ-
ously derived independent SK-Mel-239 vemurafenib-resistant
clones (C1 and C5), which attained resistance to vemurafenib
through distinct mechanisms (Poulikakos et al., 2011), by 72%
(Figure 6M) and 39% (Figure S6D), respectively, and prolonged
the survival of mice bearing vemurafenib-resistant melanoma
burden (Figure 6N). Additionally, GW3965 reduced by 50% the
growth of tumors generated by a B-Raf-mutant/vemurafenib-
resistant primary mouse subline that we derived through in vivo
selection (Figures 6O and S6E). These results reveal that LXRb
agonism is effective in suppressing multiple melanoma sublines
resistant to the widely used B-Raf kinase inhibitor vemurafenib
and the sole FDA-approved cytotoxic chemotherapeutic in mel-
anoma, dacarbazine.n
2 enhancers and introduced intomelanoma cells treated with DMSO, GW3965,
ody. The ChIP product was analyzed by qRT-PCR using primers spanning a
ed as fold enrichment relative to a genomic region lacking the LXR element
ted with DMSO, GW3965, or T0901317 at 1 mM for 72 hr. ApoE expression was
o cells treated with DMSO, GW3965, or T0901317 at 1 mM for 72 hr. nR 3.
with DMSO, GW3965, or T0901317 at 1 mM for 72 hr, in response to an ApoE
man melanoma cells treated with DMSO or GW3965 at 1 mM for 72 hr. n = 4.
or 72 hr, were subjected to the matrigel invasion (J) and endothelial recruitment
cted into MeWo cells expressing a control shRNA or shRNAs targeting LXRa or
NA or shRNAs targeting LXRa or LXRb and treated with GW3965 or T0901317
and Figure S3.
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LXRb Therapy Cooperates with Mainstay Melanoma
Therapeutics in Suppressing Melanoma Progression
We next investigated combination regimens. Namely, whereas
either GW3965 or DTIC treatment alone inhibited B16F10
tumor growth by 65% and 70%, respectively, combined
GW3965 and DTIC therapy led to a greater than 90% suppres-
sion of tumor growth (Figure 7A). We further found that
combined GW3965 and vemurafenib treatment suppressed
tumor progression by the B-Raf mutant A375 line by 82%,
which significantly exceeded the inhibition seen with each
drug alone: 44% for GW3965 and 65% for vemurafenib (Fig-
ures 7B and 7C). Additionally, alternating vemurafenib and
LXR agonist therapy was more effective on tumor growth sup-
pression (74%) than single-agent GW3965 (62%) or vemura-
fenib (57%) treatment (Figure 7D) and on survival outcomes
(Figure 7E). Such cooperativity was also evident in metastatic
colonization assays involving multiple cell lines (Figures 7F
and 7G).
Finally, we investigated cooperativity between LXRb activa-
tion and immunotherapy. Although anti-CTLA-4 antibody (Ab)
monotherapy inhibited melanoma growth by 20% (van Elsas
et al., 1999), GW3965 therapy inhibited growth by over 60%.
Remarkably, combining these agents elicited a greater than
80% inhibition in tumor growth and further improved survival
outcomes relative to each drug alone, revealing additivity be-
tween the effects of GW3965 and anti-CTLA-4 Ab therapy (Fig-
ures 7H and 7I).
In summary, we find that LXR agonist treatment suppressed
melanoma progression to a degree comparable to and/or
greater than that of the current FDA-approved mainstay mela-
noma therapeutics. Importantly, combining GW3965 treatment
with either DTIC, vemurafenib, or the anti-CTLA-4 antibody led
to significantly greater melanoma suppression than each treat-
ment alone. Our findings from combined pharmacologic, molec-
ular, and genetic studies in diverse preclinical models of
melanoma establish LXRb targeting as a promising therapeutic
approach that robustly suppresses melanoma progression
through the transcriptional induction of ApoE—a key suppressor
of melanoma invasion and metastatic angiogenesis (Pencheva
et al., 2012; Figure 7J).Figure 5. LXRb Agonism Suppresses Melanoma Progression by Induc
(A and B) Western blot measurements of ApoE protein levels in mouse adipose
(20 mg/kg) for 10 days. nR 3.
(C) ApoE mRNA levels in circulating white blood cells from mice fed a control die
(D) Tumor growth by 5 3 104 B16F10 control cells or cells expressing shRNAs t
Upon detection of tumors measuring 5–10 mm3 in volume, mice were fed a con
measured. nR 6.
(E) Tumor growth by 53 104 B16F10 control cells or B16F10-shApoE cells grafte
diet (20 mg/kg) for 7 days. nR 8.
(F–H) Cumulative percentage plots depicting ApoE staining intensity within F4/80
endothelial cells (H) within B16F10 subcutaneous tumors following treatment wit
(I) Representative confocal images showing ApoE colocalization with macrophag
(J) Lung colonization measured 22 days following intravenous injection of 5 3 10
mice. Mice were assigned to a control diet or a GW3965 diet (20 mg/kg) 10 days
(K) ApoE protein expression in nonmetastatic (n = 39) and metastatic (n = 34) pr
(L and M) Kaplan-Meier curves for the MSKCC cohort depicting metastasis-free (L
patients’ primary melanoma tumors. ApoE-pos, ApoE levels > median; ApoE –ne
All data are represented as mean ± SEM. Scale bars, 5 mm (D and E), 10 mm (I),DISCUSSION
Metastatic melanoma remains a formidable clinical challenge
(Bhatia et al., 2009). Novel targeted agents have extended sur-
vival times in subsets of patients by an average of 4–10 months
(van Elsas et al., 1999; Hodi et al., 2010; Yang et al., 2010;
Chapman et al., 2011; Sosman et al., 2012), with some patients
exhibiting durable responses to anti-CTLA-4 therapy. Despite
this, the sole path to cure for metastatic melanoma still remains
prevention of metastatic relapse, for which there currently exists
no effective therapeutic regimen (Garbe et al., 2011).
Remarkably, LXRb agonism suppressed the in vivo progres-
sion of diverse melanoma subtypes, harboring activating muta-
tions in the oncogenes B-Raf or N-Ras, inactivating mutations
in the tumor suppressors Pten or CDKN2A, or wild-type for
B-Raf and N-Ras (Hodis et al., 2012). Our results also reveal
cooperativity between this approach and the frontline regimens
dacarbazine, vemurafenib, and anti-CTLA-4 Ab. Combination
regimens incorporating LXR activation further improved mela-
noma progression outcomes relative to treatment with each
therapeutic alone. Additionally, oral delivery of LXR agonists
suppressed the progression of established lung metastases
and reduced brain metastatic colonization—an intractable clin-
ical condition that lacks an effective FDA-approved therapeutic.
We further find that LXRb agonism strongly inhibited the in vivo
growth of melanoma lines resistant to dacarbazine and vemura-
fenib. Taken together, these findings compellingly support LXRb
activation as a broad-spectrum therapy in melanoma and have
important clinical implications for patients whose melanomas
do not respond to approved agents, metastasize to the brain,
and/or develop resistance to dacarbazine or vemurafenib.
The robust melanoma-suppressive effects of LXR agonists
occurred in the absence of any noted adverse effects such as
weight loss (Figure S2A) or symptomatic health deterioration in
response to high-dose GW3965 administration in long-term
mouse experiments. LXR agonists were originally developed
and conceived of as lifelong therapies for the chronic manage-
ment of dyslipidemia. The clinical application of GW3965 and
its related congener, however, was stalled when these two com-
pounds were found to lack efficacy in reducing cholesterol levelsing Melanoma-Derived and Stromal ApoE Expression
, lung, and brain tissues in response to a control diet or an LXR agonist diet
t or an LXR agonist diet at 20 mg/kg for 10 days. nR 3.
argeting mouse LXRa or LXRb in C57BL/6-WT, LXRa/, or LXRb/ mice.
trol diet or a GW3965 diet (20 mg/kg) for 7 days, and final tumor volume was
d onto C57BL/6-WT or ApoE/mice that were fed a control diet or a GW3965
-positive macrophages (F), CD45-positive leukocytes (G), and CD31-positive
h a control diet or a GW3965 diet for 7 days.
es (F4/80), leukocytes (CD45), and endothelial cells (CD31).
4 B16F10 control cells or B16F10-shApoE cells into C57BL/6-WT or ApoE/
preceding cancer cell injection. nR 5.
imary melanoma skin lesions resected from patients at the MSKCC.
) and overall (M) survival of patients as a function of ApoE protein expression in
g, ApoE levels < median.
100 mm (K). See also Figures S4 and S5.
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in primates (Groot et al., 2005). Although there is some continued
interest in clinically developing this class for cardiovascular indi-
cations, our findings suggest promise for LXR agonists in the
management of melanoma.
Nuclear hormone receptor targeting has proved extremely
effective in managing sex-hormone-driven malignancies such
as breast and prostate cancers. However, in contrast to breast
and prostate cancers where the ‘‘antagonism’’ of estrogen and
androgen receptors, respectively, suppresses cancer progres-
sion by inhibiting the transcription of genes driving cancer prolif-
eration (Deblois and Gigue`re, 2013; Tran et al., 2009), we find
that pharmacologic ‘‘agonism’’ of LXRb inhibits the growth and
metastasis of melanoma by uniquely transcriptionally activating
the expression of a metastasis suppressor gene (ApoE) that acts
within the tumor microenvironment. We previously found that
this secreted factor suppressed melanoma invasion by binding
the LRP1 receptor on melanoma cells, whereas it suppressed
endothelial recruitment and migration by engaging endothelial
LRP8 receptors. The coordinate inhibition of these cell-autono-
mous/non-cell-autonomous phenotypes by ApoE accounts for
its remarkable activity in vivo (Pencheva et al., 2012).
LXRa and LXRb, which were cloned by multiple groups (Willy
et al., 1995; Apfel et al., 1994; Song et al., 1994), belong to a
family of nuclear hormone receptors that are endogenously
activated by various oxysterols (Janowski et al., 1996). Recently,
27-hydroxycholesterol, an oxysterol that acts as a partial LXR
agonist, was shown to promote metastatic dissemination by
murine breast cancer cells (Nelson et al., 2013). In contrast to
this, we herein report that LXR activation suppresses human
and mouse melanoma metastasis. The different roles of LXR
agonism in breast versus melanoma metastasis could be due
to cancer type-specific differences or 27-hydroxycholesterol’s
partial agonism of LXR signaling.
Although nuclear hormone receptors such as ER, AR, and LXR
transcriptionally activate multiple genes, our genetic and molec-
ular studies reveal the effects of GW3965 onmelanoma progres-
sion to be primarily mediated by a single LXRb target gene:
ApoE. While we cannot exclude that LXRb activation induces
additional targets that may contribute to melanoma suppressionFigure 6. LXRb Activation Inhibits Genetically Initiated Melanoma
Vemurafenib
(A) Survival of Tyr::CreER; BrafV600E/+; Ptenlox/+ mice fed a control diet or a GW3
(B) Melanoma tumor burden, expressed as the percentage of dorsal skin area, o
response to a control chow or a GW3965-supplemented chow. nR 4.
(C) Macroscopic metastatic nodules detected postmortem in the salivary gland
GW3965 diet. nR 7.
(D) Subcutaneous tumor growth by 1 3 105 BrafV600E/+; Pten/; CDKN2A/ pr
control diet or a GW3965 diet (100 mg/kg). nR 16.
(E) Survival of mice bearing YUMM melanoma burden shown in (D). nR 7.
(F) Lung colonization by 13 105 YUMM cells intravenously injected into C57BL/6m
diet (100 mg/kg). nR 14.
(G–I) Tumor growth by 53 104 parental (G) or DTIC-resistant (H) B16F10 cells subc
DTIC (50 mg/kg), or GW3965 (100 mg/kg). nR 7.
(J–L) Tumor growth by 53 105 parental (J) or DTIC-resistant (K) MeWo cells in res
(M) Tumor growth by 2 3 106 SK-Mel-239 vemurafenib-resistant cells (clone 1,
GW3965 diet (100 mg/kg). nR 7.
(N) Survival of mice shown in (M) postgrafting of SK-Mel-239 C1 cells. n = 7.
(O) Tumor growth by 2 3 105 vemurafenib-resistant YUMM cells in response to
All data are represented as mean ± SEM. Scale bar, 5 mm except for (B) (2 mm)along with ApoE, our findings of complete LXR agonist inactivity
upon ApoE genetic inactivation suggest that ApoE is the primary
determinant of melanoma suppression in response to LXR
agonism.
We uncover an important role for stromal ApoE in mediating
the effects of LXR agonists on melanoma progression. Interest-
ingly, whereas tumor growth inhibition was primarily driven by
ApoE induction in stromal cells, metastasis suppression by
GW3965 was elicited through the activation of both stromal
and melanoma-derived ApoE (Figures 5E and 5J). We speculate
that relative tissue-specific differences in microenvironmental
ApoE expression (lower in lung relative to skin, Figures S5B
and S5C) confer the differential impact of melanoma-derived
ApoE in suppressing tumor growth versus metastasis. The
reduced expression of ApoE in the lung relative to the skin may
provide melanoma cells a hospitable niche and, as such, may
contribute to the clinically evident organotropism of melanoma
cells for the lung.
Our findings reveal that ApoE activation therapy suppresses
metastatic initiation. We believe that this is in part due to
ApoE’s demonstrated capacity to reduce endothelial cell
recruitment by melanoma cells in vivo. How might suppressed
endothelial recruitment impact metastatic initiation? We had
previously shown that highly metastatic human breast cancer
cells (Png et al., 2012) and melanoma cells (Pencheva et al.,
2012) display enhanced ability to promote endothelial recruit-
ment in vitro and in vivo. Although angiogenesis is thought to
promote tumor growth primarily through its enhancement of
blood perfusion, we had previously found that metastatic endo-
thelial recruitment (MER) can trigger the initiation of metastases
(Png et al., 2012). The current work further supports a role for
MER in metastatic progression by revealing that ApoE activa-
tion therapy, which diminishes endothelial content within mela-
noma tumors in vivo, robustly suppresses metastatic initiation
by melanoma cells.
Advanced melanomas display tremendous molecular versa-
tility, allowing them to develop resistance to targeted therapies
(Nazarian et al., 2010; Shi et al., 2012; Prahallad et al., 2012). In
contrast, nontransformed stromal tissues are less prone toProgression and Suppresses Melanomas Resistant to DTIC and
965 diet (100 mg/kg) following general melanoma induction. nR 10.
n day 35 postmelanoma induction in Tyr::CreER; BrafV600E/+; Ptenlox/lox mice in
lymph nodes of Tyr::CreER; BrafV600E/+; Ptenlox/lox mice fed a control diet or a
imary melanoma cells (designated as YUMM) in C57BL/6 mice treated with a
ice. Following cell injection, mice were assigned to a control diet or a GW3965
utaneously grafted onto C57BL/6mice that were treated with a control vehicle,
ponse to a control, DTIC (50 mg/kg), or GW3965 (100 mg/kg) treatment. nR 6.
C1) grafted onto immunocompromised mice that were fed a control diet or a
a control, vemurafenib, or GW3965 diet. nR 8.
. See also Figure S6.
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network plasticity and the acquisition of resistance. Our findings
of chronic elevation of ApoE in nontransformed stromal tissues in
response to LXR activation suggest that patients treated with
LXR therapy may be less vulnerable to the emergence of resis-
tance. However, a solution to eventual resistance outcomes,
such as LXRb mutational and/or expression alterations, would
be the development of next-generation LXRb agonists that could
bind and activate a potentially mutated/deregulated receptor
with greater potency (O’Hare et al., 2005; Tran et al., 2009). An
alternative path would be to enhance ApoE posttranscriptionally
through locked nucleic acid (LNA)-based inhibition of melanoma
metastasis-promoting microRNAs miR-199a-3p, miR-199a-5p,
and miR-1908 that convergently target ApoE (Pencheva et al.,
2012), which might overcome potential resistance to ApoE
transcriptional activation therapy. Additionally, the feasibility of
therapeutically inducing ApoE using both pharmacologic LXR
agonism and LNA-based miRNA silencing mechanisms sug-
gests potential for therapeutic cooperativity upon combined
transcriptional/posttranscriptional ApoE modulation.EXPERIMENTAL PROCEDURES
Animal Experiments
All mouse studies were conducted according to a protocol approved by the
Institutional Animal Care and Use Committee at the Rockefeller University.
NOD SCID, NOD SCID gamma, athymic nu/nu, and C57BL/6 (WT; Tyr::CreER,
B-RafV600E/+, Ptenlox/+; LXRa/; LXRb/) mice were obtained from the Jack-
son Laboratory. For experiments testing the effect of LXR agonists on tumor
growth, mice were assigned to a control chow or a chow supplemented with
GW3965 (Sigma-Aldrich, AdooQ Bioscience) or T0901317 (Tocris Bioscience)
at 20, 75, or 100 mg/kg/day, as indicated. For therapeutic metastasis forma-
tion studies, mice were fed a control diet or an LXR agonist-supplemented
diet starting 10 days prior to cancer cell injection, unless otherwise specified.
For general melanoma induction in Tyr::CreER; B-RafV600E/+; Ptenlox/+ and
Ptenlox/lox mice, 6-week-old mice were intraperitoneally (i.p.) injected with
4-HT (70% Z-isomer, Sigma-Aldrich) at 25 mg/kg, administered in peanut oil
on 3 consecutive days, and assigned to a control diet or a GW3965 diet
(100 mg/kg). For combination drug regimens, mice were fed a GW3965-
supplemented diet and cotreated with DTIC (Sigma-Aldrich), 50 mg/kg by
i.p. injection; vemurafenib (Genentech), diet-supplemented at 50 mg/kg; and
immunoglobulin (Ig) G or anti-CTLA-4 Ab (BioXcell), 100 mg/mouse followed
by two consecutive 50 mg/mouse doses every 3 days by i.p. injection. All
drug-formulated diets were prepared by Research Diets. See Extended Exper-
imental Procedures.Figure 7. Additive Effects between LXR Agonist Therapy and Mainstay
(A) Primary tumor growth by 5 3 104 B16F10 cells grafted onto C57BL/6 mice
combined GW3965/DTIC treatment. nR 8.
(B) Tumor progression following subcutaneous grafting of 8 3 105 B-Raf mutant
control, GW3965 (75 mg/kg), vemurafenib (50 mg/kg), or combined GW3965/vem
(C) Survival of mice bearing A375 melanoma burden shown in (B). nR 4.
(D) Tumor growth by 1.253 106 B-Rafmutant SK-Mel-239 melanoma cells in resp
diet treatment. nR 8.
(E) Survival of mice shown in (D) following grafting of SK-Mel-239 tumors. nR 7
(F and G) Bioluminescence imaging of lung colonization by 13 105 SK-Mel-334.2
to a control, GW3965, vemurafenib, or combined GW3965/vemurafenib diet trea
(H) Subcutaneous tumor growth by 53 104 B16F10 cells in C57BL/6 mice that we
diet/CTLA-4 Ab + GM-CSF vaccine treatment, or CTLA-4 Ab + GW3965 combin
(I) Survival of mice bearing B16F10 tumors in response to CTLA-4 Ab, GW3965,
(J) Experimentally derived model depicting the coordinate engagement of str
suppressing melanoma progression.
All data are represented as mean ± SEM. Scale bars, 5 mm.Tissue Culture
The SK-Mel-334 primary human melanoma line was established from a soft
tissue metastasis of a B-Raf mutant melanoma patient at the MSKCC.
Following minimum expansion in vitro, the cells were in vivo selected to
generate the lung-metastatic derivatives SK-Mel-334.2. The SK-Mel-239
parental and vemurafenib-resistant cells were a gift from Poulikos Poulikakos
(Mount Sinai Medical School) and the B-RafV600E/+; Pten/; CDKN2A/
primarymurinemelanoma linewas generously provided byMarcusRosenberg
(Yale University). All other cell lines were purchased from ATCC and cultured in
standard conditions. See Extended Experimental Procedures.
ApoE ELISA
Extracellular ApoE levels in serum-free conditioned media from melanoma
cells treated with DMSO, GW3965, or T0901317 at 1 mM for 72 hr were quan-
tified using the human ApoE ELISA kit (Innovative Research).
Western Blotting
Mouse lung and brain tissues were homogenized on ice in RIPA buffer (Sigma-
Aldrich). Mouse adipose tissue was homogenized in TNET buffer (1.5 mM Tris
[pH 7.5], 150 mM NaCl, 2 mM EDTA, 1% triton, protease inhibitors). For anal-
ysis of ApoE protein expression in human melanoma cells treated with DMSO,
GW3965, or T0901317 at 1 mM for 72 hr, cells were lysed in RIPA buffer. Total
protein lysates were separated by SDS-PAGE, transferred to a PVDF mem-
brane, and blotted with antibodies against mouse ApoE (ab20874, Abcam),
human ApoE (ab1906, Abcam), and tubulin (2148, Cell Signaling Technology).
LXRb ChIP
ChIP was performed with 18 mg of sheared chromatin using the ChIP-IT High
Sensitivity kit (Active Motif) and a ChIP-optimized LXRb antibody (61177,
Active Motif). See Extended Experimental Procedures.
Histochemistry
For macroscopic lung metastatic nodule visualization, fixed lungs were
embedded in paraffin, sectioned, and hematoxylin and eosin (H&E) stained.
For analysis of tumor endothelial cell content, proliferation, and apoptosis,
paraffin-embedded tumor sections were stained with antibodies against
MECA-32 (Developmental Studies Hybridoma Bank), CD31 (DIA-310, Dia-
nova), Ki-67 (ab15580, Abcam), or cleaved caspase-3 (9661, Cell Signaling
Technology). For ApoE colocalization studies, frozen tumor sections were
double stained with antibodies against ApoE (sc-6384, Santa Cruz Biotech-
nology) F4/80 (MCA497, AbD Serotec), CD45 (550539, BD Pharmingen), and
CD31 (550274, BD Pharmingen). See Extended Experimental Procedures.
ApoE Expression Analysis in Melanoma Clinical Samples
Clinical samples were procured, processed, and analyzed in agreement with
IRB guidelines. Primary melanoma skin lesions were previously resected
from patients at the MSKCC, formalin-fixed, paraffin-embedded, and
sectioned at 5 mm intervals. ApoE protein expression was assessed byMelanoma Therapeutics
that were assigned to a control, GW3965 (100 mg/kg), DTIC (50 mg/kg), or
A375 melanoma cells into immunocompromised mice that were treated with a
urafenib diet. nR 8.
onse to a control, GW3965, vemurafenib, or alternating vemurafenib/GW3965
.
(F) and 7.53 104 HT-144 (G) B-Rafmutant human melanoma cells in response
tment. nR 5.
re assigned to a control diet/IgG, GW diet/IgG, control diet/CTLA-4 Ab, control
ation therapy. nR 8.
CTLA-4 Ab + GW3965 combination therapy, or a control treatment. nR 8.
omal and melanoma cell-autonomous ApoE by LXRb activation therapy in
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double-blinded immunohistochemical analysis using the D6E10 anti-ApoE
antibody (ab1906, Abcam). See Extended Experimental Procedures.
Data Analysis
Significance of non-Gaussian bioluminescence measurements was deter-
mined using the Mann-Whitney t test. The Mantel-Cox log-rank test was
used for statistical comparisons in survival analyses. The Kolmogorov-
Smirnov test was employed in comparing ApoE staining intensity cumulative
distributions. All other statistical comparisons were carried out using Student’s
t tests. Throughout all figures, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001. Significance was concluded at p < 0.05.
ACCESSION NUMBERS
Microarray gene expression data from the MeWo human melanoma line in
response to GW3965 treatment are deposited at Gene Expression Omnibus
(GEO) under the accession number GSE48782.
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